Orphan Drug Designation in USA

Yesterday the FDA granted the request from BioArctic Neuroscience for orphan-drug designation of heparin activated recombinant human Fibroblast Growth Factor 1 (FGF1) in combination with a ...

BioArctic founds SpineMedical AB

SpineMedical AB is a 100 percent owned subsidiary to BioArctic Neuroscience AB. The company was founded to bring the new treatment and product for complete spinal ...

Huge interest for BioArctic / Eisai symposium

BioArctic presented a symposium together with its partner Eisai at the 10th International Conference on Alzheimer´s & Parkinson´s Diseases (AD/PD) in Barcelona March 9 - 13th. ...